TargetBeta
GLP1R
glucagon like peptide 1 receptor · also GLP-1R · Glucagon receptor family
39 programs in company-led studies act on GLP1R, from 26 companies: 17 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (22 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Tirzepatiderule | Eli Lilly | phase 4 | 7220 running | GIPR | ChEMBL |
| Semaglutiderule | Novo Nordisk | phase 4 | 17018 running | – | NCIt |
| Liraglutiderule | Novo Nordisk | phase 4 | 1165 running | – | ChEMBL |
| dulaglutiderule | Eli Lilly | phase 4 | 471 running | – | NCIt |
| zenagamtide | Novo Nordisk | phase 3 | 3526 running | CALCR | a judged reading |
| orforglipronrule | Eli Lilly | phase 3 | 5017 running | – | the studies' text |
| berobenatide | Pfizer | phase 3 | 2317 running | – | the company's pipeline |
| UBT251 | The United Laboratories International | phase 3 | 1212 running | GCGR, GIPR | a judged reading |
| retatrutiderule | Eli Lilly | phase 3 | 3311 running | GCGR, GIPR | ChEMBL |
| survodutide | Boehringer Ingelheim | phase 3 | 3510 running | GCGR | the company's pipeline |
| mazdutiderule | Innovent Biologics | phase 3 | 279 running | – | the studies' text |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 259 running | – | the studies' text |
| olatorepatide | Hansoh Pharmaceutical Group | phase 3 | 127 running | GIPR | a judged reading |
| enicepatide | Hoffmann-La Roche | phase 3 | 107 running | GIPR | a judged reading |
| VK2735rule | Viking Therapeutics | phase 3 | 85 running | GIPR | the studies' text |
| MDR-001rule | MindRank AI | phase 3 | 65 running | – | the studies' text |
| DR10624rule | Huadong Medicine | phase 3 | 64 running | GCGR | the studies' text |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 193 running | – | the company's pipeline |
| efpeglenatiderule | Hanmi Pharmaceutical | phase 3 | 131 running | – | ChEMBL |
| avexitiderule | Amylyx Pharmaceuticals | phase 3 | 21 running | – | NCIt |
| edaglutide alfa | CSPC Pharmaceutical Group | phase 3 | 110 running | – | a judged reading |
| AZD9550 | AstraZeneca | phase 2 | 75 running | GCGR | a judged reading |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 64 running | GIPR, NPY2R | the company's pipeline |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 54 running | GCGR, GIPR | the company's pipeline |
| NNC0519-0130 | Novo Nordisk | phase 2 | 111 running | GIPR | a judged reading |
| NA-931rule | Biomed Industries | phase 2 | 31 running | GIPR, IGF1 | the studies' text |
| TE-8105rule | Immunwork | phase 2 | 21 running | – | the studies' text |
| danuglipronrule | Pfizer | phase 2 | 180 running | – | ChEMBL |
| efinopegdutide | Johnson & Johnson | phase 2 | 150 running | GCGR | a judged reading |
| RGT001-075rule | Regor Pharmaceuticals | phase 2 | 30 running | – | the studies' text |
| TQF3250 | Sino Biopharmaceutical | phase 1 | 33 running | – | the company's pipeline |
| IBI3042rule | Innovent Biologics | phase 1 | 22 running | – | the studies' text |
| PF-08642534 | Pfizer | phase 1 | 21 running | – | the company's pipeline |
| BLX-7006rule | Biolexis Therapeutics | phase 1 | 11 running | – | the studies' text |
| PF-08656795 | Pfizer | phase 1 | 11 running | – | the company's pipeline |
| XTL6001rule | Shanghai Xitaili Biomedicine Technology | phase 1 | 11 running | – | the studies' text |
| dapiglutiderule | Zealand Pharma | phase 1 | 40 running | – | the studies' text |
| BMF-650rule | Biomea Fusion | phase 1 | 10 running | – | the studies' text |
| CagriSema A | Novo Nordisk | phase 1 | 10 running | CALCR | a judged reading |
Conditions their studies are in
- Obesity, 34 programs
- Diabetes Mellitus, Type 2, 22 programs
- Diabetes Mellitus, 10 programs
- Non-alcoholic Fatty Liver Disease, 6 programs
- Overweight, 6 programs
- Fatty Liver, 4 programs
- Renal Insufficiency, Chronic, 3 programs
- Sleep Apnea, Obstructive, 3 programs
- Diabetes Mellitus, Type 1, 2 programs
- Lymphoma, Follicular, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026Tirzepatide · Eli Lilly · phase 4 · NCT07299084
- Nov 2026retatrutide · Eli Lilly · phase 3 · NCT06662383
- Dec 2026Semaglutide · Novo Nordisk · phase 4 · NCT07430059
- Dec 2026UBT251 · The United Laboratories International · phase 3 · NCT07785934
- Dec 2026Safiglipron · Jiangsu HengRui Medicine · phase 3 · NCT06820099
- Dec 2026TQF3250 · Sino Biopharmaceutical · phase 1 · NCT07327281
- Dec 8, 2026survodutide · Boehringer Ingelheim · phase 3 · NCT07768813
- Dec 13, 2026Liraglutide · Novo Nordisk · phase 4 · NCT07225816
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.